Post marketing safety assessment of the novel postpartum depression drug, Zuranolone
Evidence from real-world pharmacovigilance analysis based on the FDA adverse event reporting system
Dados Bibliográficos
| ID | 15523508 |
|---|---|
| Autores | Duoqin Huang (0009-0000-5952-7884, Gannan Medical University), Zixin Luo (0000-0001-6946-2826, First Affiliated Hospital of Gannan Medical University), Xi Gong (0000-0001-7899-6213, Gannan Medical University), Kang Zou (0000-0002-4959-1951, First Affiliated Hospital of Gannan Medical University), Yu Peng (0009-0008-5014-3997), Yufeng Peng (0000-0003-0942-3141, Jiangxi Pingxiang People's Hospital), Shaoying Zeng (First Affiliated Hospital of Gannan Medical University, autor correspondente) |
| Ano | 2025 |
| Volume | 16 |
| Páginas | 1517773-1517773 |
| Data de publicação | 2025-08-15 |
| Peer Reviewed | Sim |
| Open Access | Sim |
| Tipo | ARTICLE |
| Periódico | Frontiers in Psychiatry (JOURNAL) |
| Identificadores do periódico | ISSN: 1664-0640 • E-ISSN: 1664-0640 |
| Editora | Frontiers Media (PUBLISHER • CH) |
| DOI | 10.3389/fpsyt.2025.1517773 |
| PMID | 40896228 |
| OpenAlex | W4413380948 |
| Idioma | EN |
| Referências citadas | 33 |
This study revealed potential AEs of Zuranolone, confirming known safety information about Zuranolone, providing comprehensive data for medical practice and public health decision-making, and laying the foundation for further clinical research. It also provides more comprehensive and updated evidence for the clinical safety of Zuranolone
Adverse effect · Adverse Event Reporting System · Anxiety · Pharmacovigilance · Psychiatry · Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes · Maternal Mental Health During Pregnancy and Postpartum · Medicine · Pregnancy and Medication Impact · Pharmacology
| Velocidade de citação | historical |
|---|---|
| Altamente citado | Não |